Prevention or Delay of Type II Diabetes: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 10: | Line 10: | ||
| bgcolor="Seashell"|<nowiki>"</nowiki>'''3.''' Based on the cost-effectiveness of diabetes prevention, such programs should be covered by third-party payers. ''([[American Diabetes Association#Evidence Grading System|Level of Evidence: B]])''<nowiki>"</nowiki> | | bgcolor="Seashell"|<nowiki>"</nowiki>'''3.''' Based on the cost-effectiveness of diabetes prevention, such programs should be covered by third-party payers. ''([[American Diabetes Association#Evidence Grading System|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="Seashell"|<nowiki>"</nowiki>'''4.''' Metformin therapy for prevention of type 2 diabetes should be considered in those with prediabetes, especially in those with BMI | | bgcolor="Seashell"|<nowiki>"</nowiki>'''4.''' Metformin therapy for prevention of type 2 diabetes should be considered in those with prediabetes, especially in those with BMI >35 kg/m2, those aged <60 years, and women with prior gestational diabetes mellitus. ''([[American Diabetes Association#Evidence Grading System|Level of Evidence: A]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="Seashell"|<nowiki>"</nowiki>'''5.''' At least annual monitoring for the development of diabetes in those with prediabetes is suggested. ''([[American Diabetes Association#Evidence Grading System|Level of Evidence: E]])''<nowiki>"</nowiki> | | bgcolor="Seashell"|<nowiki>"</nowiki>'''5.''' At least annual monitoring for the development of diabetes in those with prediabetes is suggested. ''([[American Diabetes Association#Evidence Grading System|Level of Evidence: E]])''<nowiki>"</nowiki> |
Revision as of 17:02, 7 December 2016
2016 ADA Guideline Recommendations |
Types of Diabetes Mellitus |
---|
2016 ADA Standard of Medical Care Guideline Recommendations |
Cardiovascular Disease and Risk Management |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shivani Chaparala M.B.B.S [2]; Seyedmahdi Pahlavani, M.D. [3]; Tarek Nafee, M.D. [4]
2016 ADA Standards of Medical Care in Diabetes Guidelines
"1. Patients with prediabetes should be referred to an intensive diet and physical activity behavioral counseling program adhering to the tenets of the Diabetes Prevention Program (DPP) targeting a loss of 7% of body weight and should increase their moderate-intensity physical activity (such as brisk walking) to at least 150 min/week. (Level of Evidence: A)" |
"2. Follow-up counseling and maintenance programs should be offered for long- term success in preventing diabetes. (Level of Evidence: B)" |
"3. Based on the cost-effectiveness of diabetes prevention, such programs should be covered by third-party payers. (Level of Evidence: B)" |
"4. Metformin therapy for prevention of type 2 diabetes should be considered in those with prediabetes, especially in those with BMI >35 kg/m2, those aged <60 years, and women with prior gestational diabetes mellitus. (Level of Evidence: A)" |
"5. At least annual monitoring for the development of diabetes in those with prediabetes is suggested. (Level of Evidence: E)" |
"6. Screening for and treatment of modifiable risk factors for cardiovascular dis- ease is suggested. (Level of Evidence: B)" |
"7. Diabetes self-management education and support programs are appropriate venues for people with prediabetes to receive education and support to de- velop and maintain behaviors that can prevent or delay the onset of diabetes. (Level of Evidence: B)" |
"8. Technology-assisted tools including Internet-based social networks, distance learning, DVD-based content, and mobile applications can be useful elements of effective lifestyle modification to prevent diabetes. (Level of Evidence: B)" |